| DC Field | Value | Language |
|---|
| dc.contributor.author | Osipova, O. A. | - |
| dc.contributor.author | Drapkina, O. M. | - |
| dc.contributor.author | Kulikovskii, V. F. | - |
| dc.contributor.author | Yarosh, A. L. | - |
| dc.contributor.author | Osipov, P. G. | - |
| dc.date.accessioned | 2021-07-02T12:00:56Z | - |
| dc.date.available | 2021-07-02T12:00:56Z | - |
| dc.date.issued | 2015 | - |
| dc.identifier.citation | Pharmacological correction of immune disorders in patients with chronic heart failure and ischemic heart disease / O. A. Osipova [et al.] // Научный результат. Сер. Медицина и фармация. - 2015. - Т.1, №4(6).-С. 19-24. - doi: 10.18413/2313-8955-2015-1-4-19-24. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/42738 | - |
| dc.description.abstract | Currently, there are few data on the effect of cardiovascular drugs on the immune status of patients with heart failure (HF). This paper provides information on the impact of ß-adrenergic blocking agent (BAB), angiotensin-converting enzyme inhibitors (ACEI) on the maintenance of markers of immune inflammation in the blood, as well as on inhibition of synthesis of tumor necrosis factor-α (TNF-α) and on blocking of interaction between TNF-α and membrane receptors | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | immune inflammation | ru |
| dc.subject | chronic heart failure | ru |
| dc.subject | coronary heart disease | ru |
| dc.subject | tumor necrosis factor-α | ru |
| dc.subject | ß-blockers | ru |
| dc.subject | angiotensin-converting enzyme inhibitors | ru |
| dc.title | Pharmacological correction of immune disorders in patients with chronic heart failure and ischemic heart disease | ru |
| dc.type | Article | ru |
| Appears in Collections: | Т. 1, вып. 4
|
